Look it's neither here nor there to me if you think it's a "bucket of crap". It's based on what I've learnt speaking to industry contacts who've had to deal with this before and know a lot more about the problems sparsentan had with FDA for that FSGS trial.
Ann: Dimerix presentation at Bioshares Biotech Summit, page-35
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $211.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $246.4K | 658.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 262775 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 32276 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |